Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study.

Michael L Wang Javier L Muñoz Andre H Goy Frederick L Locke Caron A JacobsonBrian T HillJohn M TimmermanHouston HolmesSamantha JaglowskiIan W FlinnPeter A McSweeneyDavid Bernard Miklos John M Pagel Marie José KerstenKrimo BouabdallahRashmi KhanalMax S Topp Houot Roch Amer BeitinjanehWeimin PengXiang FangRhine R ShenRubina SiddiqiIoana KloosPatrick M Reagan

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)

These data, representing the longest follow-up of CAR T-cell therapy in patients with MCL to date, suggest that KTE-X19 induced durable long-term responses with manageable safety in patients with relapsed/refractory MCL and may also benefit those with high-risk characteristics.

Keyphrases

cell therapy
acute lymphoblastic leukemia
acute myeloid leukemia
multiple myeloma
diffuse large b cell lymphoma
hodgkin lymphoma
stem cells
mesenchymal stem cells
high glucose
diabetic rats
big data
endothelial cells
data analysis